zintick

Actuate Therapeutics ACTU

Actuate Therapeutics, Inc. · Nasdaq · Pharmaceutical Preparations

$0.34-9.68%close on Oct. 30, 2026 · volume 489K · Yahoo Finance

Price, last 49 sessions

$0.50$1.00$1.50Sept. 2026Oct. 2026
Aug. 24, 2026 to Oct. 30, 2026 · high $1.78 · low $0.34 · SEC filing, placed when SEC released it

Our coverage

Insider buying and selling

DateInsiderTradeSharesAvg. priceValue
Oct. 28, 2026Daniel M. Schmitt
President, CEO and Director, director
Bought140,844$0.36$50,000

Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.

Recent SEC filings

All 12 →
  • 4Oct. 30, 2026, 5:05 p.m. ETView on SEC.gov
  • SCHEDULE 13GOct. 30, 2026, 4:05 p.m. ETView on SEC.gov
  • 4Oct. 30, 2026, 3:37 p.m. ETView on SEC.gov
  • 8-KOct. 30, 2026, 4:05 p.m. ETView on SEC.govOur explainer

    Delisting notice / failure to meet listing standard

    AI summary, unreviewedActuate Therapeutics Receives Nasdaq Minimum Bid Price Deficiency Notice, Adding to Existing MVLS Non-Compliance

  • 4Oct. 29, 2026, 9:35 a.m. ETView on SEC.gov
  • 8-KOct. 28, 2026, 5:17 p.m. ETView on SEC.gov

    Entry into a material definitive agreement · Other events · Financial statements and exhibits

    AI summary, unreviewedActuate Therapeutics Prices $11.0 Million Public Offering at $0.71 per Share-and-Warrant Set, Closes for Net Proceeds of About $9.96 Million

  • 424B5Oct. 28, 2026, 8 a.m. ETView on SEC.gov
  • S-1/AOct. 19, 2026View on SEC.gov